Pharmaceuticals
InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer
NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib...
2022-04-14 08:00
2641
Happiness Development Donated Anti-epidemic Materials to Minhang District, Shanghai
NANPING, China, April 13, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) an emerging and diversified company engaging in the business of production and sale of nutraceutical and dietary supplements, providing e-commerce sales and marketing solu...
2022-04-13 20:00
2711
111, Inc. Provides Urgently-needed Items and Online Services to Support Shanghai's Fight Against Covid-19 Pandemic
SHANGHAI, April 13, 2022 /PRNewswire/ -- On April, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, has set up an "Anti-Epidemic Command" at the first opportunity to coordinate its relevant departments and manpower to fully partic...
2022-04-13 17:02
2538
AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
SHANGHAI, April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that DEXTENZA has been approved inMacau, China for...
2022-04-13 10:46
2698
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies * Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea ,April 12, 2022 /PRNewswire/ -- HanAll...
2022-04-13 08:00
2234
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022
* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve * The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 st...
2022-04-13 06:00
1676
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product
SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administrati...
2022-04-12 20:55
1270
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States
CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...
2022-04-12 15:45
1272
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/
We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...
2022-04-12 15:34
2555
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...
2022-04-11 20:00
1565
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
3643
AGC to Expand Synthetic Pharmaceutical Production Base in Spain
TOKYO, April 8, 2022 /PRNewswire/ -- AGC Inc. (hereinafter "AGC"), a Tokyo -based world-leading manufacturer of glass, chemicals, high-tech materials, has decided to expand the facilities of AGC Pharma Chemicals Europe S.L.U. (hereinafter "APCE"), an AGC subsidiary in Spain engaged in the syntheti...
2022-04-08 14:00
2314
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr.Raffaele Baffa ("Dr. Baffa") has been appointed as...
2022-04-07 23:42
3242
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced the upcoming presentation of preclinical data of H002, a next-generation epid...
2022-04-07 19:47
1887
Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada
TAIPEI, April 6, 2022 /PRNewswire/ -- Bened Biomedical announced recent approval of the company's probioticL. plantarum PS128 in Thailand and Canada. Authorities in each country also endorsed health claims that may be made about the strain. Local distributors will launch PS128 products this year....
2022-04-07 11:20
2129
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
* The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO, April 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treat...
2022-04-07 09:34
2838
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
BOSTON, April 6, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston -based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, ...
2022-04-07 04:00
2521
HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company (ticker code 688222.SH), today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical comp...
2022-04-06 22:30
2860
Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment ofSharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro d...
2022-04-06 20:00
3755
Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
* Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02). * Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors. * Proxalutamid...
2022-04-06 09:22
2151
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 305 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 286 media titles]
2026-05-27 09:16
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 281 media titles]
2026-05-21 16:31
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
9302
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8789
